A stated preference binary choice experiment to explore NICE decision making

Tappenden, Paul; Brazier, John; Ratcliffe, Julie; Chilcott, James
July 2007
PharmacoEconomics;2007, Vol. 25 Issue 8, p685
Academic Journal
journal article
Objective: To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services.Method: A stated preference binary choice experiment was used to explore the preferences of members of NICE's Appraisal Committees for incremental cost effectiveness, the degree of uncertainty surrounding incremental costs and health outcomes, the age of beneficiaries, baseline health-related quality of life (HR-QOL) and the availability of alternative therapies when considering whether to recommend health technologies.Results: A logit modelling analysis of Committee members' stated preferences suggested that increases in the incremental cost-effectiveness ratio and economic uncertainty, and the availability of other therapies was associated with statistically significant reductions in the odds of a positive recommendation (p < 0.01). The transition from a very low to a comparatively high level of baseline HR-QOL was also associated with a statistically significant reduction in the odds of a positive recommendation (p = 0.003). The age of beneficiaries did not significantly affect decisions concerning whether to recommend technologies.Conclusion: The results of the choice experiment support the notion of a probabilistic adoption/rejection approach rather than the operation of a single cost-effectiveness threshold.


Related Articles

  • A model for NICE in the US. Ferner, R. E.; McDowell, Sarah E. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/13/2009, Vol. 338 Issue 7708, p1401 

    The authors suggest a health service delivery model for the Great Britain National Institute for Health and Clinical Excellence (NICE). They compared the health care system and costs in the U.S. and Great Britain. They argued that data on comparative efficacy and cost effectiveness are needed to...

  • Estimating ‘CostsÂ’ for Cost-Effectiveness Analysis. Miners, Alec // PharmacoEconomics;2008, Vol. 26 Issue 9, p745 

    Since 1999, the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Programme has been charged with producing guidance for the NHS in England and Wales on the appropriate use of new and existing healthcare programmes. Guidance is based on an assessment of a number...

  • Co-payments to expand as NHS budget shrinks. Ireland, Tom // GP: General Practitioner;5/15/2009, p17 

    The article reports on the statement of Dr. David Jenner of General Medical Services at the British National Health Service Alliance concerning the plans of the National Institute for Health and National Excellence. He believes that NICE will develop list of services driven by the mismatch...

  • THE CONCEPT OF EXCEPTIONALITY: A LEGAL FARCE? Ford, Amy // Medical Law Review;Summer2012, Vol. 20 Issue 3, p304 

    How do we decide which treatments should be offered by the National Health Service (NHS) when we cannot afford to fund them all? In the absence of a positive appraisal by the National Institute for Health and Clinical Excellence (NICE), which mandates the provision of a treatment by the NHS,...

  • NICE considers the patient.  // PharmacoEconomics & Outcomes News;2/21/2009, Issue 572, p3 

    The article reports on a study by the British National Institute for Health & Clinical Excellence (NICE), investigating how value, to patients, is explored when new health technologies are considered, and new guidance on engaging patients in decision surrounding prescribed medicines. The...

  • Saving lives or saving money: what do we really think about NICE? Ainsworth, Steve // Nurse Prescribing;Sep2006, Vol. 4 Issue 8, p312 

    The article cites some reasons why the National Institute for Health and Clinical Excellence (NICE) has been subjected to more criticism than praise since its launch in 1999 in Great Britain. One reason is said to be the narrow focus of the priority to technology appraisal given by NICE, which...

  • Current Issues.  // PharmacoEconomics & Outcomes News;5/26/2012, Issue 654, p3 

    The article reports on the recommendation made by the Citizen's Council to the Great Britain National Institute for Clinical Excellence (NICE), for the institute not to use its standard 3.5% discount rate for costs and benefits in situations where healthcare costs are paid for upfront.

  • Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. Heeg, Bart; Damen, Joep; Van Hout, Ben // PharmacoEconomics;2007, Vol. 25 Issue 12, p1063 

    Background: A wide variety of oral antiplatelet trials have been carried out, and a large number of cost-effectiveness estimates based on them have been published.Objective: To assess the cost effectiveness of oral antiplatelet treatments in the prevention of...

  • DoH rejects call for independent NICE overhaul. Moberly, Tom // GP: General Practitioner;5/15/2009, p9 

    The article reports on the decision of the British Department of Health (DOH) to reject proposals for an independent inquiry into the National Institute for Health and Clinical Excellence's (NICE) methods and plans to include patient views in assessments. DOH rejected the proposal by venture...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics